Home > Dermatology > SPIN 2019 > Advances in Therapy > Advances in target-oriented therapy: psoriatic arthritis

Advances in target-oriented therapy: psoriatic arthritis

Expert
Prof. Wolf-Henning Boehncke, University of Geneva, Switzerland
Conference
SPIN 2019
Trial
ECLIPSA, TICOPA

Prof. Wolf-Henning Boehncke (University of Geneva, Switzerland) provided an unorthodox presentation about psoriatic arthritis (PsA), highlighting aspects that are, as he put it, “to the left and right of what is in the current limelight” [1]. He argued that the lack of PsA-focussed outcome measures has possibly hindered the progress of innovative biologics in PsA patients as the gold standard of care, and he predicts that treat-to-target using minimal disease activity as an objective will be the future of timely and effective PsA management.

Steadily increasing recognition is being awarded to the fact that -like psoriasis of the skin- PsA can be multifaceted; however, unlike rheumatoid arthritis, PsA can affect tissues beyond the joints [2]. For example, Prof. Boehncke detailed, inflammation in PsA can result in swelling of an entire toe, especially associated tendons and their entheses (attachments to bone). There is an enormous benefit in coupling the kn...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on